Fig. 4From: Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE studyMean changes from baseline on treatment for EORTC QLQ-C30 global health status. EORTC European Organisation for Research and Treatment of Cancer, IPI ipilimumab, QLQ-C30 Core Quality of Life Questionnaire, SE standard errorBack to article page